The Promotion of Peony Seed Proteolysis Product to the Immune Efficacy Induced by ptfA Gene DNA Vaccine of Avian Pasteurella multocida

2020 ◽  
Author(s):  
Qiang Gong ◽  
Zhenqi Du ◽  
Mingfu Niu ◽  
Cuili Qin
Keyword(s):  
Dna Vaccine ◽  
Pasteurella Multocida ◽  
Protective Efficacy ◽  
Stimulation Index ◽  
Serum Antibody ◽  
Peripheral Blood Lymphocytes ◽  
Vaccine Group ◽  
Live Attenuated Vaccine ◽  
Attenuated Vaccine ◽  
Immune Efficacy

Background: Avian Pasteurella multocida is one of the pathogens that affect the health of poultry. The protective efficacy of traditional attenuated vaccine is not ideal. In previous study, we prepared ptfA gene DNA vaccine of avian P. multocida. However, the protective effect of ptfA gene DNA vaccine was inferior to the attenuated vaccine. Therefore, it is necessary to improve the immune efficacy of avian P. multocida DNA vaccine, such as screening for novel adjuvant. Methods: In this study, the peony seed proteolysis product was gavaged to chickens before DNA vaccination or was added to the ptfA gene DNA vaccine as adjuvant. These vaccines were administered to chickens and the serum antibody, lymphocyte proliferation levels, IFN-g, IL-2, IL-4 and IL-6 concentrations secreted by peripheral blood lymphocytes were determined. After challenging with virulent avian P. multocida, survival time and protective efficacy was evaluated. Result: Following vaccination, no significant differences in antibody levels and concentrations of IL-4 among the DNA vaccine group, adjuvant-DNA vaccine group and gavaged group were observed. The stimulation index (SI) values, concentrations of IFN-g, IL-2 and IL-6 in adjuvant-DNA vaccine group and gavaged group were significantly higher than those in the DNA vaccine group. The protective efficacy of live attenuated vaccine group, DNA vaccine group, adjuvant-DNA vaccine group and gavaged group were 92%, 52%, 72% and 60%, respectively. This study has laid a foundation for the design and application of future DNA vaccines of P. multocida and DNA vaccine adjuvant.

scholarly journals The immune response and protective efficacy of a potential DNA vaccine against virulent Pasteurella multocida

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Ahmed A. M. Yassein ◽  
Ayaat A. Teleb ◽  
Gamal M. Hassan ◽  
Zaki A. El Fiky
Keyword(s):  
Dna Vaccine ◽  
Pasteurella Multocida ◽  
Protective Efficacy ◽  
High Titer ◽  
Serum Antibody ◽  
Rflp Analysis ◽  
Elisa Test ◽  
Farm Animals ◽  
Serum Samples ◽  
Live Attenuated Vaccine

Abstract Background Pasteurella multocida is the main cause of several infections of farm animals, and the immunity gained from commercial vaccines is for the short term only and needs to be routinely administered, so work on new vaccines against virulent P. multocida is crucial. Results In this study, the OmpH gene was amplified from ten P. multocida strains, and the PCR products were sequenced and analyzed. The results of RFLP analysis of OmpH gene digested by MspI enzyme showed that all of ten strains examined possessed one restriction site and two fragments, 350 and 650 bp. The OmpH sequence of strain No. 10 was cloned into bacterial expression vector pUCP24, and the recombinant pUCP24-OmpH was expressed in E. coli DH5α. Serum samples obtained from the ELISA test from a group of vaccinated rats indicate that the antibodies were present at high titer in immunized rats and can be tested as a vaccine candidate with a challenge. Conclusions In rats infected with the DNA vaccine and inactivated vaccine, a significant increase in serum antibody levels was observed. In addition, the DNA vaccine provided the vaccinated rats with partial protection; however, the protective efficacy was greater than that offered by the live attenuated vaccine. This successful recombinant vaccine is immunogenic and may potentially be used as a vaccine in the future.

scholarly journals Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2

iScience ◽  
2021 ◽  
pp. 102941
Author(s):  
Jun-Guy Park ◽  
Fatai S. Oladunni ◽  
Mohammed A. Rohaim ◽  
Jayde Whittingham-Dowd ◽  
James Tollitt ◽  
...  
Keyword(s):  
Protective Efficacy ◽  
Live Attenuated Vaccine ◽  
Attenuated Vaccine

scholarly journals Improved stability of live attenuated vaccine gdhA derivative Pasteurella multocida B:2 by freeze drying method for use as animal vaccine

Cryobiology ◽  
2017 ◽  
Vol 79 ◽  
pp. 1-8 ◽  
Author(s):  
Siti Nur Hazwani Oslan ◽  
Murni Halim ◽  
Nurfahanah Amirah Ramle ◽  
Mohd Zamri Saad ◽  
Joo Shun Tan ◽  
...  
Keyword(s):  
Freeze Drying ◽  
Pasteurella Multocida ◽  
Drying Method ◽  
Live Attenuated Vaccine ◽  
Attenuated Vaccine ◽  
Improved Stability

Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in Mice and Ferrets

Vaccine ◽  
2011 ◽  
Vol 29 (4) ◽  
pp. 698-705 ◽  
Author(s):  
PengHui Yang ◽  
YueQiang Duan ◽  
Cheng Wang ◽  
Li Xing ◽  
Xiao Gao ◽  
...  
Keyword(s):  
Protective Efficacy ◽  
Live Attenuated Vaccine ◽  
Attenuated Vaccine

scholarly journals Protective efficacy of a recombinant plague vaccine when co-administered with another sub-unit or live attenuated vaccine

2005 ◽  
Vol 43 (3) ◽  
pp. 425-430 ◽  
Author(s):  
Kate Griffin ◽  
Richard Bedford ◽  
Kate Townson ◽  
Robert Phillpotts ◽  
Simon Funnell ◽  
...  
Keyword(s):  
Protective Efficacy ◽  
Live Attenuated Vaccine ◽  
Attenuated Vaccine ◽  
Plague Vaccine

scholarly journals Immune effects against influenza A virus and a novel DNA vaccine with co-expression of haemagglutinin- and neuraminidase-encoding genes

2009 ◽  
Vol 58 (7) ◽  
pp. 845-854 ◽  
Author(s):  
Weidong Zhang ◽  
Wanyi Li ◽  
Yan Li ◽  
Hong Li ◽  
Baoning Wang ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Dna Vaccine ◽  
Influenza A ◽  
Protective Efficacy ◽  
Survival Rates ◽  
Serum Antibody ◽  
Lethal Challenge ◽  
Vector Systems

The high variability of influenza virus causes difficulties in the control and prevention of influenza, thus seeking a promising approach for dealing with these problems is a hot topic. Haemagglutinin (HA) and neuraminidase (NA) are major surface antigens of the influenza virus, and provide effective protection against lethal challenges with this virus. We constructed a DNA vaccine (pHA-IRES2-NA) that co-expressed both HA and NA, and compared its protective efficacy and immunogenic ability with that of singly expressed HA or NA, or a mixture of the two singly expressed proteins. Our findings showed that both HA and NA proteins expressed by pHA-IRES2-NA could be detected in vivo and in vitro. The protection of DNA vaccines was evaluated by serum antibody titres, residual lung virus titres and survival rates of the mice. In the murine model, immunization of pHA-IRES2-NA generated significant anti-HA and anti-NA antibody, increased the percentage of CD8+ cells and gamma interferon-producing CD8+ cells and the ratio of Th1/Th2 (T helper) cells, which was comparable to the effects of immunization with HA or NA DNA alone or with a mixture of HA and NA DNA. All the mice inoculated by pHA-IRES2-NA resisted the lethal challenge by homologous influenza virus and survived with low lung virus titre. In addition, previous studies reported that co-expression allowed higher-frequency transduction compared to co-transduction of separated vector systems encoding different genes. The novel HA and NA co-expression DNA vaccine is a successful alternative to using a mixture of purified HA and NA proteins or HA and NA DNA.

Sign in / Sign up

Export Citation Format

Share Document